Published in Semin Oncol on December 01, 2013
Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol (2014) 1.16
Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. JAMA Oncol (2016) 1.13
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin (2014) 1.12
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol (2014) 1.00
Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. EJC Suppl (2014) 0.91
Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol (2014) 0.91
Default mode network as a potential biomarker of chemotherapy-related brain injury. Neurobiol Aging (2014) 0.87
Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations. Brain Imaging Behav (2013) 0.86
Association of cancer history with Alzheimer's disease onset and structural brain changes. Front Physiol (2014) 0.86
Review complementary and integrative interventions for cancer-related cognitive changes. Asia Pac J Oncol Nurs (2015) 0.84
Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging (2015) 0.83
Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav (2013) 0.83
Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. Alzheimers Dement (2016) 0.83
Moderate Physical Activity Mediates the Association between White Matter Lesion Volume and Memory Recall in Breast Cancer Survivors. PLoS One (2016) 0.81
Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psychooncology (2015) 0.77
Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol (2016) 0.77
Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study. Soc Sci Med (2016) 0.76
Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment. Oncologist (2016) 0.75
Perceived cognitive function for breast cancer survivors: association of genetic and behaviorally related variables for inflammation. Support Care Cancer (2017) 0.75
Delirium diagnosis, screening and management. Curr Opin Support Palliat Care (2014) 0.75
Biomarkers Associated with Cognitive Impairment in Treated Cancer Patients: Potential Predisposition and Risk Factors. Front Pharmacol (2017) 0.75
Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults. Am J Geriatr Psychiatry (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci (2001) 42.21
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol (2007) 16.55
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc (2006) 6.81
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Trajectories of disability in the last year of life. N Engl J Med (2010) 5.55
Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci (2003) 5.11
Estrogen receptors and human disease. J Clin Invest (2006) 4.91
Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging (2005) 4.88
The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci (2004) 4.84
Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science (2004) 4.74
Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol (2012) 4.25
The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer (2004) 3.50
Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci (2000) 3.45
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol (2002) 3.13
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer (2007) 3.12
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer (2010) 2.88
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc (2002) 2.79
Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry (2009) 2.70
Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change. Health Psychol (2004) 2.56
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol (2010) 2.52
The reliability theory of aging and longevity. J Theor Biol (2001) 2.48
Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer (2007) 2.43
The identification of frailty: a systematic literature review. J Am Geriatr Soc (2011) 2.41
CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol (2006) 2.34
Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol (2012) 2.33
Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ (2012) 2.32
Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med (2005) 2.30
A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology (1997) 2.30
Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol (2004) 2.24
Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat (2006) 2.17
Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA (1998) 2.14
International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol (2011) 2.06
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause (2007) 2.04
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol (2008) 2.01
Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc (2003) 2.00
The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology (2003) 2.00
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol (2012) 1.99
Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol (2004) 1.97
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95
Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol (2007) 1.94
Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex (2004) 1.91
The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn (2005) 1.91
Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat (2010) 1.89
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc (2009) 1.87
Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev (2004) 1.79
A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol (2006) 1.79
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol (2010) 1.75
Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv (2007) 1.74
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology (1996) 1.74
Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res (2003) 1.71
Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol (2008) 1.71
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology (2012) 1.67
Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc (2010) 1.60
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc (2006) 1.57
Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med (1996) 1.57
The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav (2006) 1.55
Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry (2003) 1.53
Preliminary evidence for subdimensions of geriatric frailty: the MacArthur study of successful aging. J Am Geriatr Soc (2008) 1.52
Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol (2012) 1.49
Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun (2012) 1.48
Estrogen and cognitive aging in women. Neuroscience (2005) 1.44
Self-efficacy and memory aging: the impact of a memory intervention based on self-efficacy. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2008) 1.44
Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol (2012) 1.43
Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology (2007) 1.41
Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol (2012) 1.41
Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp (2011) 1.40
Linking DNA damage and neurodegeneration. Trends Neurosci (2000) 1.40
Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun (2012) 1.40
Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol (2011) 1.39
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol (2008) 1.34
A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care (2005) 1.34
Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev (2010) 1.33
Age-related decline in brain resources modulates genetic effects on cognitive functioning. Front Neurosci (2008) 1.33
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology (2009) 1.28
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
Adjusting for global effects in voxel-based morphometry: gray matter decline in normal aging. Neuroimage (2012) 1.27
Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun (2012) 1.27
Neurocognitive changes in cancer survivors. Cancer J (2008) 1.27
Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev (2012) 1.26
Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care (2007) 1.25
Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis (2007) 1.24
Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer (2010) 1.23
Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr Rev (1995) 1.23
Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses (2006) 1.23
Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med J (2005) 1.21
Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol (2002) 1.21
Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet (1996) 1.21
Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci (2010) 1.19
Altered small-world properties of gray matter networks in breast cancer. BMC Neurol (2012) 1.19
Frailty for Surgeons: Review of a National Institute on Aging Conference on Frailty for Specialists. J Am Coll Surg (2015) 0.81